BCL6 and diffuse large B-cell lymphoma: In a study of 64 newly diagnosed DLBCL treated with anthracycline-based therapies, Chen et al. reported that loss of 6q and gain of 3q were associated with shorter time to treatment failure.38 Gains of 3q25-q27 were also found to correlate shorter patient survival and elevated BCL6 expression.37 Gain of BCL6, which occurred in 8% of our cases, was identified as one of our top hits from 3q27.3, and was associated with failure to achieved EFS24 (P=0.003).